Cubist Systematic Strategies’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-52,383
| Closed | -$215K | – | 4744 |
|
|
2022
Q1 | $215K | Buy |
52,383
+41,054
| +362% | +$149K | ﹤0.01% | 3017 |
|
|
2021
Q4 | $40K | Buy |
+11,329
| New | +$39.6K | ﹤0.01% | 3334 |
|
|
2021
Q3 | – | Sell |
-18,631
| Closed | -$81K | – | 3296 |
|
|
2021
Q2 | $81K | Sell |
18,631
-27,392
| -60% | -$112K | ﹤0.01% | 2740 |
|
|
2021
Q1 | $189K | Sell |
46,023
-1,929
| -4% | -$8.36K | ﹤0.01% | 2496 |
|
|
2020
Q4 | $191K | Sell |
47,952
-4,943
| -9% | -$16K | ﹤0.01% | 2256 |
|
|
2020
Q3 | $143K | Sell |
52,895
-140,797
| -73% | -$390K | ﹤0.01% | 2221 |
|
|
2020
Q2 | $533K | Buy |
193,692
+128,847
| +199% | +$360K | 0.01% | 1557 |
|
|
2020
Q1 | $153K | Sell |
64,845
-25,130
| -28% | -$85.5K | ﹤0.01% | 1810 |
|
|
2019
Q4 | $423K | Buy |
+89,975
| New | +$368K | 0.01% | 1646 |
|
|
2019
Q2 | – | Sell |
-16,153
| Closed | -$49K | – | 2645 |
|
|
2019
Q1 | $49K | Buy |
+16,153
| New | +$52.3K | ﹤0.01% | 2109 |
|
|
2018
Q2 | – | Sell |
-13,513
| Closed | -$30K | – | 2140 |
|
|
2018
Q1 | $30K | Sell |
13,513
-40,200
| -75% | -$90.5K | ﹤0.01% | 1736 |
|
|
2017
Q4 | $107K | Buy |
+53,713
| New | +$117K | 0.01% | 1674 |
|
Other funds holding ATRS
Cubist Systematic Strategies's ATRS Position: Q2 2022 in Review
Cubist Systematic Strategies sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 52,383 shares — an estimated $215K sold.
Cubist Systematic Strategies first reported a position in ATRS in Q4 2017 and held it in 12 quarters. The position peaked at $533K in Q2 2020. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Cubist Systematic Strategies reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Cubist Systematic Strategies sold 52,383 Antares Pharma, Inc. shares in Q2 2022, an estimated $215K.
- Cubist Systematic Strategies first reported a position in Antares Pharma, Inc. in Q4 2017 and held it in 12 quarters.
- Cubist Systematic Strategies's Antares Pharma, Inc. position peaked at $533K in Q2 2020.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Cubist Systematic Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.